Press release BoxID: 936148 (Noxxon Pharma AG)

Noxxon Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, de
http://www.noxxon.net

Contact person
Aram Mangasarian
+49 (30) 726247101

Noxxon announces participation in the East/West CEO forum in San Francisco, in january 2019

(PresseBox) ( Berlin, Germany, 18-12-20 )

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that the company will participate in the East/West CEO Forum – an invite-only event that brings together the global leaders of the biopharma community. The forum will be held on January 5-6, 2019, at the Four Seasons Hotel, 757 Market Street, San Francisco, CA 94103, USA.

Aram Mangasarian, Chief Executive Officer of NOXXON, will join the panel discussion "Europe Biotech Market Outlook" on Saturday, January 5, 2019, from 04.35 p.m. to 05.05 p.m. PST.

Mr. Mangasarian and Dr. Jarl Ulf Jungnelius, Chief Medical Officer of NOXXON, will also be available for meetings in San Francisco during the Annual J.P. Morgan Healthcare Conference, January 6-10.

Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

Noxxon Pharma AG

NOXXON's oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor microenvironment, NOXXON's approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 has delivered top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in 2018 and further studies are being planned in these indications. The company initiated an additional trial with NOX-A12 in brain cancer in combination with radiotherapy, for which an orphan drug status has been granted in the US and EU. The company's second asset, NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors both as a monotherapy and in combination. Further information can be found at: www.noxxon.com

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.